Journal Specialty Index  

Oncology

Topic	Issue
Case Review: The Role of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer With Visceral Metastatic Breast Cancer With Visceral Metastasis	AUGUST 2025 • VOL. 17 • NO. 7
Case Review: The Role of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer With Visceral Metastatic Breast Cancer With Visceral Metastasis	MARCH 2025 • VOL. 17 • NO. 2
Addition of Abemaciclib to Hormonal Therapy Shows Improved Disease Control in HR+/HER2- Advanced Breast Cancer	MARCH 2025 • VOL. 17 • NO. 2
The Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma	MARCH 2025 • VOL. 17 • NO. 2
The Clinical Significance of Nutritional Therapy in Optimising Outcomes of Cancer Patients	DECEMBER 2024 • VOL. 16 • NO. 13
Understanding Minimal Residual Disease in Early-Stage Colorectal Cancer: The Role of Circulating Tumour DNA for MRD Assessment	DECEMBER 2024 • VOL. 16 • NO. 13
Enhancing Survival in Metastatic Hormone-Sensitive Prostate Cancer: A New Standard for Treatment Intensification	DECEMBER 2024 • VOL. 16 • NO. 13
ADC Therapy and Patient Identification Using NGS to Improve Outcomes in HER2m Metastatic NSCLC	DECEMBER 2024 • VOL. 16 • NO. 13
Management of Third-Generation Target Therapy Resistance in Adenocarcinoma of the Lung	OCTOBER 2024 • VOL. 16 • NO. 10
Latest Survival Outcomes for Lung Cancer in Hong Kong: A Focus on Advanced Stages and Novel Treatments	OCTOBER 2024 • VOL. 16 • NO. 10
Lung Cancer Screening by Computed Tomography and Incidental Subcentimetre Lung Nodules on CT Images	OCTOBER 2024 • VOL. 16 • NO. 10
Antibody-Drug Conjugates as a New Frontier for Metastatic Triple-Negative Breast Cancer	JULY 2024 • VOL. 16 • NO. 7
Enhancing Advanced Renal Cell Carcinoma Outcomes With Adjuvant Immunotherapy	JULY 2024 • VOL. 16 • NO. 7
Targeted Therapy for the Management of Pancreatic Cancer	JULY 2024 • VOL. 16 • NO. 7
Current Treatment Landscape and Future Directions of Immunotherapy for Urothelial Carcinoma	JULY 2024 • VOL. 16 • NO. 7
Clinical Unmet Needs of Patients With Gastroenteropancreatic Neuroendocrine Tumours in Hong Kong	DECEMBER 2023 • VOL. 15 • NO. 11
Immunotherapy Regimens for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives	DECEMBER 2023 • VOL. 15 • NO. 11
Prevention of Anal Cancers: The ANCHOR Trial Results and Implications for Clinical Care	NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10
HPV-Associated Oropharyngeal Cancer in Hong Kong: How Distinct Is It? Could It Be the Next Epidemic Disease in Our Locality?	NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10
A Snapshot of the Human Papillomavirus	NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10
Adjuvant Abemaciclib Shows Deepening Disease-Free Survival Benefits in High-Risk HR+, HER2-, Node-Positive Early Breast Cancer	JUNE 2023 ‧ VOL. 15 ‧ NO. 4
A New Paradigm Shift in NSCLC Treatment – Neoadjuvant Immunotherapy Plus Chemotherapy	JUNE 2023 ‧ VOL. 15 ‧ NO. 4
Optimising mCRPC Management With Genetic Testing	JUNE 2023 ‧ VOL. 15 ‧ NO. 4
Adjuvant Immunotherapy Options for Early Non-Small Cell Lung Cancer	JUNE 2023 ‧ VOL. 15 ‧ NO. 4
Gastric Cancer Screening	MAY 2023 ‧ VOL. 15 ‧ NO. 3
An Update on Current State-Of-The-Art Investigative Modalities for the Small Bowel	MAY 2023 ‧ VOL. 15 ‧ NO. 3
A Review on the Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma	MAY 2023 ‧ VOL. 15 ‧ NO. 3
Targeted Approach to Optimise Treatment for GEP-NETs After Early Progression	NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10
Immunotherapy as First-Line Treatment for Unresectable Metastatic MSI-H/dMMR Colorectal Cancer	NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10
Olaparib Plus Bevacizumab Provides an Overall Survival Benefit for Patients With Advanced HRD+ Ovarian Cancer	NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10
Urothelial Cancer: Burden of Disease and Treatment Paradigm	NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10
Lung Cancer Patients With No EGFR Mutation. Eligible for Oral Targeted Therapy?	SEPTEMBER 2022 ‧ VOL. 14 ‧ NO. 8
"I've HER2 There Was a Secret Chord": Antibody-Drug Conjugates for Breast Cancer	JUNE 2022 ‧ VOL. 14 ‧ NO. 5
Advanced but Less Lethal: ALK-Targeted Therapy for Non-small Cell Lung Cancer	JUNE 2022 ‧ VOL. 14 ‧ NO. 5
Advanced Gastric Cancer: Current Treatment Landscape	JUNE 2022 ‧ VOL. 14 ‧ NO. 5
The Long Game on Non-small Cell Lung Cancer: 5-Year Updates From the PACIFIC Trial	JUNE 2022 ‧ VOL. 14 ‧ NO. 5
Novel Faecal Bacterial Markers for Colon Cancer and Polyp Detection	MARCH 2022 ‧ VOL. 14 ‧ NO. 2
Age Strategy for Colorectal Cancer Screening in Average-Risk Populations: Insights From US Recommendations	MARCH 2022 ‧ VOL. 14 ‧ NO. 2
Two Sex-Specific Cancers, One Targeted Therapy: Review of the Use of a PARP Inhibitor in Advanced Prostate and Ovarian Cancers	NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8
Understanding Bone Metastases and Their Management	NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8
Immunotherapy - First-Line Standard of Care for Advanced Non-small Cell Lung Cancer Treatment in Hong Kong	NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8
Disseminated Mycobacterium szulgai Infection Mimicking Lung Cancer	NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8
Update on the Use of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Thrombosis	SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7
Turning Theory Into Action: Integrating Clinical Data With Real-World Evidence in Breast Cancer Treatment	JUNE 2021 ‧ VOL. 13 ‧ NO. 6
Updates in the Management of Advanced Endometrial Cancer	JUNE 2021 ‧ VOL. 13 ‧ NO. 6
Sequence Makes a Difference: Maximizing the Potential PFS Gains With Ramucirumab Plus Erlotinib in EGFR-Positive NSCLC	JUNE 2021 ‧ VOL. 13 ‧ NO. 6
Early Access to Dacomitinib for First-Line EGFR Mutation-Positive Non-Small Cell Lung Cancer Patients	JUNE 2021 ‧ VOL. 13 ‧ NO. 6
Diagnosis for Lung Cancer: CT Guided, Endobronchial Ultrasound or Electromagnetic Navigation?	MAY 2021 ‧ VOL. 13 ‧ NO. 5
Oral Contraceptives, Hormone Replacement Therapy and Breast Cancer Risk	APRIL 2021 ‧ VOL. 13 ‧ NO. 4
40 Years of Endoscopic Ultrasound	FEBRUARY 2021 ‧ VOL. 13 ‧ NO. 2
Antibody-Drug Conjugate: A Rising HER2- Targeted Therapy for Multiple Solid Cancers	AUGUST 2020 ‧ VOL. 12 ‧ NO. 7
New Frontiers in Breast Cancer Management	JUNE 2020 ‧ VOL. 12 ‧ NO. 6
Targeting Mismatch Repair Defects with Immune Checkpoint Inhibitors as the First Tumour- Agnostic Cancer Treatment	JUNE 2020 ‧ VOL. 12 ‧ NO. 6
Personalized Treatment of Metastatic Colorectal Cancer by Tumour Sidedness	JUNE 2020 ‧ VOL. 12 ‧ NO. 6
Chemotherapy or Hormonal Therapy for Metastatic Castration-Resistant Prostate Cancer?	JUNE 2020 ‧ VOL. 12 ‧ NO. 6
Oral Targeted Therapy, Can It Be More Durable in the Treatment of Lung Cancer in Asian Patients?	MAY 2020 ‧ VOL. 12 ‧ NO. 5
Cancer-Associated Thrombosis Treatment Decision Pathway	JANUARY 2020 ‧ VOL. 12 ‧ NO. 1
Serrated Lesions in Colorectal Cancer Screening	JANUARY 2020 ‧ VOL. 12 ‧ NO. 1
Genetic Versus Genomic Testing in Cancer Management	NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8
Cardio-oncology - Where Breast Cancer and Cardiovascular Disease Intersect	JULY 2019 ‧ VOL. 11 ‧ NO. 5
Precision Medicine and Cancer Prevention - A Time of Transformation	MAY 2019 ‧ VOL. 11 ‧ NO. 4
What are the Consequences in not Performing Endobronchial Ultrasound (EBUS)?	MAY 2019 ‧ VOL. 11 ‧ NO. 4
First-line Treatment of Metastatic Non Small-Cell Lung Cancer with Immunotherapy Monotherapy	MARCH 2019 ‧ VOL. 11 ‧ NO. 2
Immune-related Adverse Event of Cancer Immunotherapy	MARCH 2019 ‧ VOL. 11 ‧ NO. 2
Colorectal Cancer Screening: Evidence and Emerging Issues	JANUARY 2019 ‧ VOL. 11 ‧ NO. 1
Update on the Management of Adult Acute Lymphoblastic Leukaemia	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
A Step Forward for the Management of Patients with Follicular Lymphoma?	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agent (Venetoclax)	SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6
Lung Cancer and Immuno-Oncology in 2018	MAY 2018 ‧ VOL. 10 ‧ NO. 4
Complete Response to Bevacizumab and Chemotherapy in an Elderly Patient with Metastatic Colorectal Cancer	JANUARY 2018 ‧ VOL. 10 ‧ NO. 1
Curing Blood Cancers: No More Chemotherapy	NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7
Good's Syndrome: An Acquired Immunodeficiency Associated with Thymomas	SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6
Osimertinib: A New Weapon Against the Acquired Resistance Mutation EGFR T790M in Non-small Cell Lung Cancer	MAY 2017 ‧ VOL. 9 ‧ NO. 4
Endobronchial Ultrasound (EBUS) for Assessing the Suitability of Biologics and Immunotherapy in Lung Cancer	MAY 2017 ‧ VOL. 9 ‧ NO. 4
Lung Cancer in the Young and Nonsmokers	MAY 2017 ‧ VOL. 9 ‧ NO. 4
Exploring a New Era of Second-line NSCLC Treatment	JANUARY 2017 ‧ VOL. 9 ‧ NO. 1
Blood Cancers: No More Chemotherapy?	NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7
Lung Cancer - Q & A	MARCH 2016 ‧ VOL. 8 ‧ NO. 3
Hodgkin Lymphoma and Use of Brentuximab Vedotin in its Treatment	JANUARY 2016 ‧ VOL. 8 ‧ NO. 1
Lymphoma: New Age, New Drugs, New Survival	NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6
Medical Nutrition Therapy for Cancer Cachexia Patients	JANUARY 2015 ‧ VOL. 7 ‧ NO. 1
Personalized Treatments for Metastatic Colorectal Cancer	JUNE 2014 ‧ VOL. 6 ‧ NO. 3
EGFR-Negative: Can I Use Oral Targeted Therapy?	JANUARY 2014 ‧ VOL. 6 ‧ NO. 1
Role of Chemotherapy in Soft Tissue Sarcoma	MARCH 2012 ‧ VOL. 4 ‧ NO. 2
Treatment of Metastatic Colorectal Carcinoma	DECEMBER 2011 ‧ VOL. 3 ‧ NO. 7
Management of Early-stage Breast Cancer	MAY 2011 ‧ VOL. 3 ‧ NO. 3
Targeted Therapy in Non-small Cell Lung Cancer	DECEMBER 2010 ‧ VOL. 2 ‧ NO. 8
Colon Cancer - The Rising Star	NOVEMBER 2010 ‧ VOL. 2 ‧ NO. 7
Clinical Evidence of the Quadrivalent HPV Vaccine in Adult Women over 26	MAY 2010 ‧ VOL. 2 ‧ NO. 3
Recent Advances in Cancer Treatment	JANUARY 2010 ‧ VOL. 2 ‧ NO. 1
Towards Earlier Diagnosis of Lung Cancer	JANUARY 2010 ‧ VOL. 2 ‧ NO. 1
Towards Earlier Diagnosis of Lung Cancer	DECEMBER 2009 ‧ VOL. 1 ‧ NO. 6
Advances in Oncology 2009	DECEMBER 2009 ‧ VOL. 1 ‧ NO. 6